<DOC>
	<DOCNO>NCT03051477</DOCNO>
	<brief_summary>This study seek determine safety toxicity profile well maximum tolerate dose Helixor® M patient advance solid tumor .</brief_summary>
	<brief_title>Dose Escalating Trial Mistletoe Extract Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study Phase I study consist two phase : dose escalation phase expansion phase . The dose escalation phase use evaluate safety toxicity Helixor® M ( mistletoe extract ) . An accelerated titration design ( ATD ) utilize determine MTD . The expansion phase use obtain preliminary efficacy data Helixor® M .</detailed_description>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>1 . Patients advance solid tumor least one line therapy metastatic disease ( chemotherapy , immunotherapy , hormonal therapy standard treatment ) 2 . Have measurable disease 3 . ECOG Performance Status 0 2 4 . Adequate organ function define studyspecified laboratory test 5 . Must use acceptable form birth control study 28 day final dose study drug 6 . Signed informed consent form 7 . Willing able comply study procedures 1 . Patient known history evidence brain metastasis 2 . Patient chemotherapy , radiation , hormonal , biological cancer therapy within 28 day prior first dose study drug 3 . Patient currently participate participate study investigational agent use investigational device within 28 day first dose study drug 4 . Patients surgery within 28 day dose investigational agent , exclude minor procedure ( dental work , skin biopsy , etc ) , celiac plexus block , biliary stent placement 5 . Patient expect require form systemic localize antineoplastic therapy study 6 . Patient prior treatment Mistletoe ( injection infusion ) 7 . Patients receive systemic corticosteroid within 28 day prior first dose study drug 8 . Patients receive systemic NSAID therapy within 14 day prior first dose study drug 9 . History allergic reaction attribute compound similar chemical biologic composition Mistletoe 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 11 . Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) ; CNS motor neuropathy consider autoimmune origin ( e.g. , GuillainBarre Syndrome Myasthenia Gravis , multiple sclerosis ) . History Grave 's disease stable thyroid hormone replacement least 1 year allow 12 . Patients known history HIV , hepatitis B , hepatitis C , tuberculosis infection . Patients history clear hepatitis C ( undetectable viral load ) allow . 13 . Women positive pregnancy test enrollment prior investigational product administration 14 . Women pregnant breastfeed 15 . Sexually active fertile men use effective birth control partner child bear potential 16 . Patient unwilling unable comply study procedure and/ schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>